| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 71 | 2025 | 391 | 15.850 |
Why?
|
| Tuberculosis | 49 | 2025 | 270 | 13.330 |
Why?
|
| Tuberculosis, Pulmonary | 21 | 2024 | 108 | 6.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2024 | 648 | 6.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 21 | 2025 | 621 | 4.570 |
Why?
|
| Tuberculosis Vaccines | 11 | 2020 | 29 | 3.810 |
Why?
|
| Antigens, Bacterial | 23 | 2023 | 200 | 3.400 |
Why?
|
| Lung | 27 | 2025 | 920 | 3.230 |
Why?
|
| Macrophages | 27 | 2024 | 1015 | 3.220 |
Why?
|
| Antigens, CD1 | 26 | 2010 | 42 | 2.630 |
Why?
|
| Lymphocyte Activation | 18 | 2017 | 743 | 2.500 |
Why?
|
| T-Lymphocyte Subsets | 16 | 2021 | 245 | 2.500 |
Why?
|
| Interferon-gamma | 25 | 2021 | 551 | 2.340 |
Why?
|
| Mice, Inbred C57BL | 40 | 2025 | 3241 | 2.310 |
Why?
|
| Mice | 83 | 2025 | 10309 | 2.310 |
Why?
|
| Animals | 104 | 2025 | 19683 | 2.160 |
Why?
|
| T-Lymphocytes | 21 | 2023 | 986 | 1.950 |
Why?
|
| Macrophages, Alveolar | 3 | 2024 | 61 | 1.910 |
Why?
|
| Apoptosis | 11 | 2021 | 1033 | 1.480 |
Why?
|
| Immunologic Memory | 6 | 2017 | 281 | 1.450 |
Why?
|
| Immune Evasion | 6 | 2017 | 55 | 1.440 |
Why?
|
| Macrophages, Peritoneal | 3 | 2018 | 73 | 1.360 |
Why?
|
| Mice, Knockout | 29 | 2021 | 1999 | 1.330 |
Why?
|
| Antigen Presentation | 18 | 2015 | 227 | 1.310 |
Why?
|
| Natural Killer T-Cells | 8 | 2020 | 27 | 1.290 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2023 | 281 | 1.220 |
Why?
|
| Host-Pathogen Interactions | 4 | 2019 | 240 | 1.100 |
Why?
|
| Cytokines | 9 | 2025 | 912 | 1.040 |
Why?
|
| Mycobacterium bovis | 2 | 2023 | 27 | 1.000 |
Why?
|
| Monocytes | 4 | 2020 | 345 | 0.970 |
Why?
|
| Killer Cells, Natural | 11 | 2011 | 218 | 0.960 |
Why?
|
| Eicosanoids | 4 | 2016 | 25 | 0.930 |
Why?
|
| Dendritic Cells | 10 | 2014 | 515 | 0.910 |
Why?
|
| Bacterial Proteins | 10 | 2019 | 738 | 0.910 |
Why?
|
| Phagocytosis | 3 | 2019 | 260 | 0.900 |
Why?
|
| Antigens, CD1d | 16 | 2013 | 28 | 0.860 |
Why?
|
| Galectins | 3 | 2012 | 7 | 0.860 |
Why?
|
| Receptors, Virus | 2 | 2016 | 67 | 0.850 |
Why?
|
| Bacillus | 1 | 2023 | 13 | 0.840 |
Why?
|
| Type VII Secretion Systems | 1 | 2023 | 8 | 0.840 |
Why?
|
| Neutrophils | 3 | 2015 | 365 | 0.810 |
Why?
|
| Epitopes, T-Lymphocyte | 7 | 2020 | 177 | 0.790 |
Why?
|
| Bacterial Infections | 4 | 2019 | 140 | 0.760 |
Why?
|
| Immunity | 2 | 2019 | 101 | 0.720 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 109 | 0.720 |
Why?
|
| Humans | 68 | 2024 | 59473 | 0.700 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2020 | 70 | 0.700 |
Why?
|
| CD11 Antigens | 1 | 2020 | 15 | 0.690 |
Why?
|
| BCG Vaccine | 6 | 2023 | 45 | 0.690 |
Why?
|
| Signal Transduction | 9 | 2019 | 2902 | 0.690 |
Why?
|
| Genome | 1 | 2022 | 257 | 0.680 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2017 | 73 | 0.670 |
Why?
|
| Female | 38 | 2025 | 30775 | 0.640 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2019 | 19 | 0.640 |
Why?
|
| Mice, Inbred C3H | 10 | 2010 | 173 | 0.590 |
Why?
|
| Immunodominant Epitopes | 3 | 2015 | 56 | 0.570 |
Why?
|
| Mice, Transgenic | 8 | 2022 | 1206 | 0.550 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 2054 | 0.550 |
Why?
|
| Cells, Cultured | 14 | 2019 | 2095 | 0.530 |
Why?
|
| Disease Resistance | 1 | 2016 | 23 | 0.530 |
Why?
|
| Interleukins | 1 | 2016 | 80 | 0.530 |
Why?
|
| Vaccines | 1 | 2018 | 95 | 0.520 |
Why?
|
| Histocompatibility Antigens Class II | 8 | 2021 | 182 | 0.520 |
Why?
|
| Immunity, Innate | 10 | 2019 | 774 | 0.500 |
Why?
|
| Macrophage Activation | 3 | 2012 | 118 | 0.500 |
Why?
|
| Interleukin-1beta | 3 | 2021 | 258 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 677 | 0.490 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 5 | 2016 | 15 | 0.480 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 111 | 0.480 |
Why?
|
| Galactosylceramides | 4 | 2013 | 11 | 0.470 |
Why?
|
| Cell Differentiation | 9 | 2021 | 1304 | 0.470 |
Why?
|
| Thymus Gland | 7 | 2021 | 229 | 0.470 |
Why?
|
| Dinoprostone | 4 | 2013 | 44 | 0.460 |
Why?
|
| Vaccination | 5 | 2022 | 335 | 0.460 |
Why?
|
| Antigen-Presenting Cells | 7 | 2021 | 177 | 0.450 |
Why?
|
| Th1 Cells | 3 | 2011 | 174 | 0.450 |
Why?
|
| Up-Regulation | 2 | 2013 | 365 | 0.440 |
Why?
|
| Interleukin-1 | 1 | 2014 | 157 | 0.430 |
Why?
|
| Immunotherapy | 2 | 2014 | 228 | 0.430 |
Why?
|
| Antibodies, Blocking | 2 | 2012 | 40 | 0.420 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 62 | 0.410 |
Why?
|
| Interferon Type I | 1 | 2014 | 169 | 0.400 |
Why?
|
| Caspase 3 | 1 | 2013 | 103 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2011 | 588 | 0.380 |
Why?
|
| Flow Cytometry | 4 | 2018 | 645 | 0.370 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2010 | 147 | 0.370 |
Why?
|
| Antitubercular Agents | 2 | 2010 | 76 | 0.370 |
Why?
|
| Interleukin-2 | 3 | 2021 | 164 | 0.350 |
Why?
|
| Isoniazid | 1 | 2010 | 11 | 0.340 |
Why?
|
| Vaccines, DNA | 2 | 2008 | 96 | 0.340 |
Why?
|
| Membrane Proteins | 3 | 2012 | 850 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 10 | 2011 | 868 | 0.330 |
Why?
|
| Immunocompromised Host | 2 | 2009 | 101 | 0.330 |
Why?
|
| Macaca mulatta | 2 | 2022 | 228 | 0.320 |
Why?
|
| Biomarkers | 5 | 2019 | 1306 | 0.320 |
Why?
|
| Phospholipids | 3 | 2013 | 78 | 0.310 |
Why?
|
| Mycobacterium Infections | 2 | 2008 | 16 | 0.310 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 29 | 0.310 |
Why?
|
| Molecular Sequence Data | 12 | 2010 | 1953 | 0.310 |
Why?
|
| Perforin | 1 | 2008 | 31 | 0.310 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 661 | 0.310 |
Why?
|
| Hybridomas | 5 | 2013 | 64 | 0.300 |
Why?
|
| Pneumonia | 1 | 2011 | 282 | 0.300 |
Why?
|
| Rheumatic Diseases | 1 | 2009 | 38 | 0.300 |
Why?
|
| Transcriptome | 2 | 2022 | 343 | 0.300 |
Why?
|
| Amino Acid Sequence | 11 | 2010 | 1555 | 0.300 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 7 | 2019 | 119 | 0.300 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 170 | 0.290 |
Why?
|
| Haplotypes | 3 | 2004 | 115 | 0.280 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 365 | 0.270 |
Why?
|
| Adoptive Transfer | 3 | 2016 | 148 | 0.270 |
Why?
|
| Interleukin-12 | 5 | 2014 | 123 | 0.270 |
Why?
|
| Spleen | 6 | 2011 | 480 | 0.260 |
Why?
|
| Interleukin-17 | 2 | 2021 | 88 | 0.260 |
Why?
|
| Gene Expression Regulation | 3 | 2011 | 1554 | 0.260 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2006 | 14 | 0.260 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 214 | 0.260 |
Why?
|
| Communicable Diseases | 1 | 2007 | 85 | 0.250 |
Why?
|
| Macaca fascicularis | 2 | 2022 | 46 | 0.250 |
Why?
|
| CD11c Antigen | 1 | 2005 | 8 | 0.250 |
Why?
|
| Major Histocompatibility Complex | 3 | 2004 | 86 | 0.250 |
Why?
|
| Pulmonary Alveoli | 1 | 2005 | 44 | 0.240 |
Why?
|
| Male | 14 | 2021 | 27796 | 0.240 |
Why?
|
| Granuloma | 3 | 2022 | 41 | 0.240 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 3 | 2011 | 24 | 0.230 |
Why?
|
| Cell Line | 9 | 2021 | 1984 | 0.220 |
Why?
|
| Lymph Nodes | 3 | 2014 | 215 | 0.220 |
Why?
|
| Mice, Inbred Strains | 5 | 2004 | 180 | 0.220 |
Why?
|
| Genetic Background | 1 | 2023 | 5 | 0.210 |
Why?
|
| Complementarity Determining Regions | 2 | 2020 | 36 | 0.210 |
Why?
|
| Necrosis | 4 | 2013 | 140 | 0.210 |
Why?
|
| Virulence | 4 | 2013 | 188 | 0.210 |
Why?
|
| Arthritis, Rheumatoid | 3 | 1998 | 322 | 0.210 |
Why?
|
| Immunoglobulin Variable Region | 3 | 1998 | 31 | 0.200 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 428 | 0.200 |
Why?
|
| B-Lymphocytes | 6 | 2007 | 550 | 0.200 |
Why?
|
| Immunity, Cellular | 3 | 2013 | 171 | 0.200 |
Why?
|
| Endosomes | 6 | 2013 | 170 | 0.200 |
Why?
|
| Autoimmune Diseases | 3 | 1995 | 221 | 0.190 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2021 | 6 | 0.190 |
Why?
|
| H-2 Antigens | 3 | 2010 | 64 | 0.190 |
Why?
|
| Cell Respiration | 1 | 2021 | 21 | 0.190 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2021 | 5 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2022 | 79 | 0.190 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2021 | 5 | 0.190 |
Why?
|
| Adaptive Immunity | 2 | 2014 | 98 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2021 | 70 | 0.190 |
Why?
|
| Mitochondria | 3 | 2021 | 343 | 0.180 |
Why?
|
| Interleukin-18 | 2 | 2014 | 71 | 0.180 |
Why?
|
| Enzyme Activation | 2 | 2013 | 359 | 0.180 |
Why?
|
| Survival Rate | 2 | 2021 | 801 | 0.180 |
Why?
|
| Bone Marrow | 1 | 2021 | 177 | 0.180 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2020 | 9 | 0.170 |
Why?
|
| Inflammation | 4 | 2019 | 1099 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 135 | 0.170 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2020 | 29 | 0.170 |
Why?
|
| Genes, Immunoglobulin | 2 | 1991 | 32 | 0.170 |
Why?
|
| Mucous Membrane | 1 | 2020 | 20 | 0.170 |
Why?
|
| Macaca | 1 | 2020 | 29 | 0.170 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1991 | 42 | 0.170 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2019 | 11 | 0.170 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2013 | 10 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 322 | 0.160 |
Why?
|
| Lysosomes | 3 | 2012 | 160 | 0.160 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 1999 | 6 | 0.160 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2019 | 1 | 0.160 |
Why?
|
| Intracellular Space | 1 | 2019 | 34 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1999 | 36 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2020 | 143 | 0.160 |
Why?
|
| Lymphoid Tissue | 3 | 2008 | 55 | 0.160 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2009 | 23 | 0.150 |
Why?
|
| Interleukin-10 | 2 | 2016 | 149 | 0.150 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 234 | 0.150 |
Why?
|
| Thioglycolates | 1 | 2018 | 7 | 0.150 |
Why?
|
| Glycolipids | 3 | 2008 | 44 | 0.150 |
Why?
|
| Listeria | 1 | 2018 | 11 | 0.150 |
Why?
|
| Lipids | 4 | 2011 | 301 | 0.150 |
Why?
|
| Elbow Joint | 1 | 1998 | 13 | 0.150 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 254 | 0.150 |
Why?
|
| Bursitis | 1 | 1998 | 15 | 0.140 |
Why?
|
| Candida | 1 | 1998 | 35 | 0.140 |
Why?
|
| Candidiasis | 1 | 1998 | 45 | 0.140 |
Why?
|
| HIV Infections | 2 | 2020 | 914 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 318 | 0.140 |
Why?
|
| Models, Immunological | 3 | 2013 | 85 | 0.140 |
Why?
|
| PPAR gamma | 1 | 2017 | 72 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 90 | 0.140 |
Why?
|
| Cell Separation | 2 | 2016 | 145 | 0.140 |
Why?
|
| Blotting, Western | 1 | 2018 | 584 | 0.130 |
Why?
|
| Middle Aged | 7 | 2020 | 16337 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 56 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 89 | 0.130 |
Why?
|
| Antigens | 3 | 2023 | 146 | 0.130 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Clone Cells | 5 | 2000 | 106 | 0.130 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1151 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2010 | 1471 | 0.120 |
Why?
|
| CD28 Antigens | 1 | 1995 | 60 | 0.120 |
Why?
|
| B7-1 Antigen | 1 | 1995 | 73 | 0.120 |
Why?
|
| Lipoxins | 3 | 2013 | 7 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2017 | 942 | 0.120 |
Why?
|
| Synovial Fluid | 2 | 2010 | 29 | 0.120 |
Why?
|
| Microbial Viability | 2 | 2012 | 57 | 0.120 |
Why?
|
| Adult | 6 | 2020 | 15698 | 0.120 |
Why?
|
| Immune Tolerance | 2 | 2013 | 172 | 0.120 |
Why?
|
| Phagosomes | 2 | 2013 | 54 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 205 | 0.120 |
Why?
|
| Cardiolipins | 2 | 2013 | 6 | 0.120 |
Why?
|
| Aged | 4 | 2020 | 13424 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 446 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 295 | 0.120 |
Why?
|
| Transfection | 5 | 2003 | 675 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 264 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2014 | 185 | 0.110 |
Why?
|
| Genotype | 3 | 2019 | 619 | 0.110 |
Why?
|
| Leishmania | 1 | 2013 | 12 | 0.110 |
Why?
|
| Nitric Oxide | 3 | 2021 | 146 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 98 | 0.110 |
Why?
|
| Tryptophan | 1 | 2013 | 54 | 0.110 |
Why?
|
| Cell Membrane | 4 | 2013 | 487 | 0.110 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2013 | 2 | 0.100 |
Why?
|
| Guinea Pigs | 3 | 2002 | 102 | 0.100 |
Why?
|
| Autoantibodies | 2 | 1991 | 172 | 0.100 |
Why?
|
| Cross-Priming | 1 | 2013 | 16 | 0.100 |
Why?
|
| Protein Transport | 4 | 2008 | 399 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2019 | 102 | 0.100 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2013 | 202 | 0.100 |
Why?
|
| Toll-Like Receptors | 4 | 2013 | 426 | 0.100 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 67 | 0.100 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 298 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 133 | 0.100 |
Why?
|
| Interleukin-4 | 3 | 2002 | 145 | 0.100 |
Why?
|
| Gene Expression | 2 | 2014 | 810 | 0.090 |
Why?
|
| Radiation Chimera | 1 | 2011 | 57 | 0.090 |
Why?
|
| Young Adult | 2 | 2020 | 4275 | 0.090 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 10 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 4 | 2002 | 836 | 0.090 |
Why?
|
| Conserved Sequence | 2 | 2002 | 171 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 394 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 439 | 0.090 |
Why?
|
| Bacteria | 1 | 2013 | 278 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 428 | 0.090 |
Why?
|
| Immunity, Mucosal | 1 | 2011 | 49 | 0.090 |
Why?
|
| Viral Vaccines | 1 | 2011 | 47 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 48 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2010 | 6 | 0.090 |
Why?
|
| Abetalipoproteinemia | 1 | 2010 | 1 | 0.090 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2010 | 11 | 0.090 |
Why?
|
| Vaccinia virus | 1 | 2010 | 71 | 0.090 |
Why?
|
| Organ Specificity | 2 | 2008 | 183 | 0.090 |
Why?
|
| Viral Envelope Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 28 | 0.090 |
Why?
|
| Caspase 1 | 1 | 2010 | 107 | 0.080 |
Why?
|
| Synovial Membrane | 1 | 2010 | 19 | 0.080 |
Why?
|
| Adolescent | 2 | 2020 | 5852 | 0.080 |
Why?
|
| Salmonella Vaccines | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 559 | 0.080 |
Why?
|
| Chromatin | 1 | 2014 | 602 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 515 | 0.080 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2009 | 24 | 0.080 |
Why?
|
| Cell Wall | 1 | 2010 | 116 | 0.080 |
Why?
|
| Mycolic Acids | 2 | 2002 | 15 | 0.080 |
Why?
|
| Superantigens | 2 | 2001 | 10 | 0.080 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2008 | 12 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 68 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 451 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 296 | 0.080 |
Why?
|
| Tuberculin Test | 1 | 2008 | 9 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 450 | 0.080 |
Why?
|
| Acyltransferases | 1 | 2008 | 31 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2011 | 815 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 40 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 209 | 0.070 |
Why?
|
| Mycobacterium avium | 2 | 2021 | 5 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2010 | 717 | 0.070 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 187 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2010 | 377 | 0.070 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 57 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2014 | 184 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 591 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2022 | 357 | 0.070 |
Why?
|
| Vaccines, Subunit | 1 | 2007 | 40 | 0.070 |
Why?
|
| Cell Death | 1 | 2008 | 271 | 0.070 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2006 | 6 | 0.070 |
Why?
|
| L-Selectin | 1 | 2006 | 14 | 0.070 |
Why?
|
| Leukocyte Common Antigens | 1 | 2006 | 58 | 0.070 |
Why?
|
| Epitopes | 1 | 2007 | 286 | 0.070 |
Why?
|
| CD11a Antigen | 1 | 2006 | 1 | 0.070 |
Why?
|
| Saponins | 1 | 2006 | 28 | 0.070 |
Why?
|
| CD18 Antigens | 1 | 2006 | 30 | 0.060 |
Why?
|
| DNA | 1 | 1991 | 806 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2005 | 18 | 0.060 |
Why?
|
| Borrelia burgdorferi | 1 | 2006 | 68 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2010 | 697 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 53 | 0.060 |
Why?
|
| Multigene Family | 2 | 1999 | 92 | 0.060 |
Why?
|
| fas Receptor | 1 | 2005 | 55 | 0.060 |
Why?
|
| Health Personnel | 1 | 2008 | 342 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1368 | 0.060 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 6 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2003 | 17 | 0.050 |
Why?
|
| Methanol | 1 | 2003 | 13 | 0.050 |
Why?
|
| Chromatography, Thin Layer | 1 | 2003 | 18 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 98 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 1139 | 0.050 |
Why?
|
| Mycoses | 1 | 2003 | 45 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 32 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 157 | 0.050 |
Why?
|
| Immunity, Active | 1 | 2002 | 10 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2003 | 114 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2005 | 391 | 0.050 |
Why?
|
| Base Sequence | 4 | 1998 | 1302 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 296 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2001 | 11 | 0.050 |
Why?
|
| Thymocytes | 1 | 2021 | 19 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 38 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 203 | 0.050 |
Why?
|
| Cathepsins | 1 | 2001 | 34 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 76 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 805 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2003 | 339 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2021 | 138 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1233 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 91 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 160 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2002 | 248 | 0.040 |
Why?
|
| Mutation | 1 | 1989 | 2458 | 0.040 |
Why?
|
| Oligonucleotide Probes | 2 | 1991 | 43 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5292 | 0.040 |
Why?
|
| South Africa | 1 | 2019 | 10 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 71 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 1999 | 64 | 0.040 |
Why?
|
| Oregon | 1 | 2019 | 19 | 0.040 |
Why?
|
| Dendrites | 1 | 1999 | 56 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 1999 | 61 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 1999 | 48 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 34 | 0.040 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 4 | 0.040 |
Why?
|
| Lymphoma, T-Cell | 1 | 1999 | 22 | 0.040 |
Why?
|
| Bronchi | 1 | 2019 | 82 | 0.040 |
Why?
|
| Models, Molecular | 3 | 2011 | 1128 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2011 | 375 | 0.040 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1998 | 27 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 450 | 0.040 |
Why?
|
| Lipoproteins | 1 | 1998 | 80 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1119 | 0.040 |
Why?
|
| Oligopeptides | 1 | 1998 | 128 | 0.040 |
Why?
|
| Gastric Mucosa | 1 | 1998 | 51 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 1998 | 14 | 0.040 |
Why?
|
| Immune System | 1 | 2019 | 129 | 0.040 |
Why?
|
| Intestines | 1 | 2019 | 158 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 1998 | 55 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 1998 | 58 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 1998 | 100 | 0.030 |
Why?
|
| Lyme Disease | 1 | 1998 | 104 | 0.030 |
Why?
|
| Stem Cells | 1 | 1999 | 255 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2002 | 100 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 1997 | 21 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 1143 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 1997 | 627 | 0.030 |
Why?
|
| Animals, Outbred Strains | 1 | 2016 | 7 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 2009 | 46 | 0.030 |
Why?
|
| Protein Binding | 2 | 2011 | 1555 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 1997 | 88 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 34 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 81 | 0.030 |
Why?
|
| Clonal Anergy | 1 | 1995 | 23 | 0.030 |
Why?
|
| Liver | 2 | 2011 | 796 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 326 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 226 | 0.030 |
Why?
|
| Cell Communication | 1 | 1995 | 124 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 1995 | 31 | 0.030 |
Why?
|
| Retroviridae | 1 | 1995 | 69 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1995 | 108 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2006 | 763 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2014 | 19 | 0.030 |
Why?
|
| Autoantigens | 1 | 1995 | 129 | 0.030 |
Why?
|
| Proteomics | 1 | 2016 | 264 | 0.030 |
Why?
|
| ortho-Aminobenzoates | 1 | 2013 | 7 | 0.030 |
Why?
|
| Neurons | 1 | 1999 | 865 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 851 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Biosynthetic Pathways | 1 | 2013 | 18 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 176 | 0.030 |
Why?
|
| Endocytosis | 3 | 2001 | 149 | 0.030 |
Why?
|
| Asthma | 1 | 1998 | 460 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1994 | 343 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2013 | 80 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 2 | 0.030 |
Why?
|
| Phosphatidylglycerols | 1 | 2013 | 12 | 0.030 |
Why?
|
| Corynebacterium glutamicum | 1 | 2013 | 4 | 0.030 |
Why?
|
| Mycobacterium smegmatis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Bacterial Secretion Systems | 1 | 2013 | 10 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 37 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2013 | 24 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 276 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 203 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2013 | 35 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 56 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 146 | 0.020 |
Why?
|
| Species Specificity | 2 | 2002 | 329 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 226 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 32 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1991 | 17 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 58 | 0.020 |
Why?
|
| Crystallization | 1 | 2011 | 97 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 93 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2011 | 89 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 133 | 0.020 |
Why?
|
| Disulfides | 1 | 2010 | 62 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2010 | 68 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 293 | 0.020 |
Why?
|
| Synaptotagmins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2009 | 33 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2009 | 39 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 69 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 656 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 68 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2009 | 63 | 0.020 |
Why?
|
| Kinetics | 1 | 1991 | 751 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2010 | 132 | 0.020 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2008 | 1 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2003 | 526 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2008 | 2 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1998 | 2060 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2010 | 187 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 41 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 881 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 354 | 0.020 |
Why?
|
| Mycobacterium | 2 | 1998 | 36 | 0.020 |
Why?
|
| Information Systems | 1 | 2007 | 29 | 0.020 |
Why?
|
| Acupuncture Therapy | 1 | 1987 | 13 | 0.020 |
Why?
|
| Shoulder | 1 | 1987 | 24 | 0.020 |
Why?
|
| Neck | 1 | 1987 | 46 | 0.020 |
Why?
|
| Diglycerides | 1 | 2006 | 23 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 250 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 691 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1097 | 0.020 |
Why?
|
| Pain Management | 1 | 1987 | 146 | 0.010 |
Why?
|
| Software | 1 | 2007 | 366 | 0.010 |
Why?
|
| Internet | 1 | 2007 | 449 | 0.010 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 70 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2008 | 695 | 0.010 |
Why?
|
| Leukemia | 1 | 1983 | 57 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 979 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2003 | 165 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1983 | 192 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 307 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 9 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 192 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2002 | 104 | 0.010 |
Why?
|
| Disaccharides | 1 | 2001 | 10 | 0.010 |
Why?
|
| Cathepsin L | 1 | 2001 | 21 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 43 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 288 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 411 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 110 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 92 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 490 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 271 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 160 | 0.010 |
Why?
|
| Pseudogenes | 1 | 1999 | 12 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 18 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 1999 | 15 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 164 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 46 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 105 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 356 | 0.010 |
Why?
|
| Spirochaetales | 1 | 1998 | 4 | 0.010 |
Why?
|
| Fixatives | 1 | 1998 | 17 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 381 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 170 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 4989 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 394 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 174 | 0.010 |
Why?
|
| Mycobacterium leprae | 1 | 1997 | 6 | 0.010 |
Why?
|
| Mannosides | 1 | 1996 | 5 | 0.010 |
Why?
|
| Coated Pits, Cell-Membrane | 1 | 1996 | 5 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1996 | 32 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1996 | 35 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1996 | 49 | 0.010 |
Why?
|
| HLA-D Antigens | 1 | 1996 | 19 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 288 | 0.010 |
Why?
|
| United States | 1 | 2008 | 7432 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1953 | 191 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1953 | 170 | 0.010 |
Why?
|
| Child | 1 | 1998 | 4205 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1953 | 737 | 0.000 |
Why?
|
| Electric Stimulation Therapy | 1 | 1987 | 27 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1987 | 713 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1983 | 11 | 0.000 |
Why?
|
| Thymidine | 1 | 1983 | 25 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1983 | 184 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1987 | 5125 | 0.000 |
Why?
|